NLRP3 and melanoma: In 2010, using the poorly immunogenic B16-F10 melanoma model, van Deventer et al. showed that the Nlrp3 inflammasome suppressed the mouse response to dendritic cell tumor vaccines through MDSC recruitment (van Deventer et al., 2010).